Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS)

Charles Schwab Investment Management Inc. grew its holdings in Bioventus Inc. (NYSE:BVS) by 11.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 435,344 shares of the company’s stock after buying an additional 45,182 shares during the period. Charles Schwab Investment Management Inc. owned 0.54% of Bioventus worth $4,571,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of BVS. Plato Investment Management Ltd acquired a new stake in Bioventus in the 4th quarter valued at about $38,000. Virtus Fund Advisers LLC purchased a new stake in shares of Bioventus in the third quarter valued at approximately $42,000. Quest Partners LLC acquired a new stake in shares of Bioventus in the third quarter valued at approximately $51,000. Quarry LP purchased a new position in Bioventus during the third quarter worth approximately $59,000. Finally, EP Wealth Advisors LLC acquired a new position in Bioventus during the third quarter worth $144,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Trading Down 3.0 %

BVS opened at $9.43 on Wednesday. The business’s 50 day moving average price is $10.12 and its 200 day moving average price is $11.01. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a market capitalization of $772.73 million, a PE ratio of -15.46 and a beta of 0.86. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Analyst Ratings Changes

BVS has been the subject of a number of recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Insider Activity

In other news, CEO Robert E. Claypoole sold 28,786 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. The trade was a 30.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the transaction, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,161 shares of company stock valued at $436,364 in the last quarter. Insiders own 32.90% of the company’s stock.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.